Topical steroid withdrawal syndrome may signal a reminder to clinicians to be good stewards of topical treatments, according ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

who are patients refractory to steroid taper or those likely to be glucocorticoid intolerant because of comorbidities. That’s where the need is.” The trial was funded by Eli Lilly, which ...

FOMO on steroids! Thus, no one can be surprised that the number of incoming GLP-1s to rival Novo Nordisk and Eli Lilly’s products is astounding. Many should be coming to market within the next ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets for high-quality clinical trials have been recognised as robust and ...

Other companies are working in this areas, notably Eli Lilly which has a BTLA4 agonist ... unlike current therapies such as steroids or TNF and interleukin inhibitors that while effective are ...

Arcutis Biotherapeutics has a lofty goal for 2025 — and it could help Arcutis stock continue a massive run that helped shares ...

4) Eli Lilly and Almirall's Ebglyss (lebrikizumab ... of choice for moderate-to-severe atopic dermatitis when topical steroids are inadequate and make sales of $6 billion. 5) Sanofi and ...

the active ingredient in Eli Lilly's Zepbound and Mounjaro. The drug-making behemoths fiercely oppose that compounding business. Novo Nordisk and Lilly lump the compounders together with internet ...

Of note, this HSP90 exposure depends on the cytotoxic agent bortezomib and does not occur after γ-irradiation or treatment with steroids ... Gemcitabine (Gemzar; Eli Lilly) is another synthetic ...